Valuation: IGM Biosciences, Inc.

Market Cap 76.57M 66.45M 62.21M 56.91M 107M 7.28B 109M 728M 286M 3.64B 287M 281M 12.13B P/E 2023
-1.76x
P/E 2024 -1.89x
Enterprise Value -62.03M -53.83M -50.39M -46.11M -86.93M -5.9B -88.23M -590M -231M -2.95B -233M -228M -9.83B EV / Sales 2023
88,302,162x
EV / Sales 2024 83,883,966x
Free-Float
56.71%
Yield 2023 *
-
Yield 2024 -
1 year 1.27
Extreme 1.27
1.31
3 years 0.92
Extreme 0.92
22.5
5 years 0.92
Extreme 0.92
86.91
10 years 0.92
Extreme 0.92
133
Manager TitleAgeSince
Chief Executive Officer - 2025-08-13
Chief Tech/Sci/R&D Officer - 2018-12-31
Chief Tech/Sci/R&D Officer - 2017-12-31
Date Insider Type Main position Quantity % Market Cap.
8/14/25 Issuer sale

Director

54,235 0.1592%
8/14/25
Topsøe Holding A/S
Issuer saleCompany 5,044,295 16.5208%
8/14/25 Issuer sale

Chief Executive Officer

323,680 0.9498%
Change 5-day change 1-year change 3-year change Capi.($)
-2.31%-.--%-0.78%-85.98% 76.57M
-3.25%+12.81%+52.96%+88.86% 64.9B
+0.69%-2.81%+25.84%+68.41% 54.05B
-1.07%-1.89%-17.90%-14.36% 23.16B
+33.86%+28.54%+18.76%+502.77% 21.46B
+1.87%+5.08%+29.88%-7.94% 21.25B
-0.79%+0.54%+31.17%-25.84% 17.94B
-3.37%+19.44%+211.98%+369.13% 17.03B
+3.29%+2.09%+17.32%+586.49% 14.99B
-7.94%-5.66%+39.35%+157.52% 14.25B
Average -1.18%+3.03%+40.86%+163.91% 24.91B
Weighted average by Cap. -1.09%+3.64%+41.93%+146.94%

Financials

2023 2024
Net sales 2.13 1.85 1.73 1.58 2.99 202.59 3.03 20.26 7.95 101.34 8 7.82 337.39 2.68 2.32 2.18 1.99 3.75 254.81 3.81 25.48 9.99 127.46 10.06 9.84 424.35
Net income -246M -214M -200M -183M -345M -23.44B -351M -2.34B -919M -11.72B -925M -905M -39.03B -196M -170M -159M -146M -274M -18.62B -278M -1.86B -730M -9.32B -735M -719M -31.01B
Net Debt -297M -258M -241M -221M -416M -28.27B -423M -2.83B -1.11B -14.14B -1.12B -1.09B -47.07B -139M -120M -113M -103M -194M -13.18B -197M -1.32B -517M -6.59B -520M -509M -21.95B
Logo IGM Biosciences, Inc.
IGM Biosciences LLC, formerly known asIGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins.
Employees
16
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. IGMS Stock